Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from KalVista Pharmaceuticals ( (KALV) ).
On October 6, 2025, KalVista Pharmaceuticals announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer. These appointments come as the company advances the global launch of EKTERLY, with Arif’s expertise in operations and Aspesi’s in human resources expected to play crucial roles in supporting the company’s growth and commitment to individuals living with HAE.
The most recent analyst rating on (KALV) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company’s strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock’s score reflects financial struggles counterbalanced by strategic opportunities.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals is a global pharmaceutical company focused on delivering oral therapies for rare diseases with significant unmet needs. The company is known for EKTERLY, the first and only oral on-demand treatment for hereditary angioedema (HAE), and works closely with the global HAE community to enhance treatment and care.
Average Trading Volume: 1,344,364
Technical Sentiment Signal: Sell
Current Market Cap: $598.7M
For an in-depth examination of KALV stock, go to TipRanks’ Overview page.